#United States #ESSA Pharma #South San Francisco #NASDAQ EPIX #XenoTherapeutics

ESSA Pharma Inc. Adjourns Special Shareholders Meeting

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, September 10, 2025 – In a significant development for investors, ESSA Pharma Inc. (NASDAQ: EPIX) has decided to adjourn its special shareholders meeting initially scheduled for September 10, 2025. The meeting will now take place online on September 29, 2025, at 2:00 p.m. PT. This change comes as ESSA aims to provide ample time for further discussions concerning the proposed transaction with XenoTherapeutics, Inc.

Context of the Adjournment

The board of directors made this decision to ensure all parties involved have the opportunity to review and potentially revise the financial terms associated with this noteworthy arrangement. XenoTherapeutics, a non-profit organization focused on biotechnological advancements, is set to acquire all outstanding common shares of ESSA. With this adjournment, shareholders, optionholders, and warrantholders can expect more concrete details surrounding the company’s financial forecasting and the anticipated cash distribution related to this transaction.

Online Meeting Details

Shareholders who have already cast their votes do not need to take any action ahead of the new date. The upcoming shareholders meeting will be conducted via a live online interactive webcast, accessible through the link: https://meetnow.global/MHPMJ4R. This format allows shareholders who might not be able to attend physically to follow along and participate in the discussions effectively.

Delay in Court Hearing

Moreover, the approval hearing for ESSA's application to British Columbia's Supreme Court, previously set for September 12, 2025, has also been postponed. The company will provide updates regarding the rescheduled hearing date through subsequent press releases, ensuring transparency in its communication with shareholders.

About ESSA Pharma Inc.

ESSA Pharma is a biotechnology company dedicated to developing innovative therapies for patients suffering from prostate cancer. Its commitment to advancing healthcare through effective treatments remains steadfast. For additional insights and updates, interested parties can visit ESSA's official website at www.essapharma.com.

Forward-Looking Statements

It's crucial to mention that this announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements acknowledge the challenges and uncertainties that could lead to results differing from those projected. While the company expresses optimism about the transaction and its anticipated benefits, many variables remain in play that may impact outcomes.

Conclusion

In conclusion, ESSA Pharma's decision to adjourn the special shareholder meeting reflects its commitment to making informed decisions that benefit its shareholders. This forthcoming online meeting and further details on the revised transaction terms with XenoTherapeutics will be crucial in shaping the future of ESSA. Stakeholders are encouraged to remain vigilant for updates as this pivotal date approaches.